Biocryst Pharmaceuticals And Green Cross Enter Agreement To Develop And Commercialize Peramivir In South Korea

BIRMINGHAM, Ala., June 14 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX - News) today announced an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst’s potent influenza neuraminidase inhibitor. Under the terms of this agreement, Green Cross will conduct clinical trials with peramivir in South Korea and will share with BioCryst all data from these studies. While facilitating development of peramivir in South Korea, these trials will also add important data to BioCryst’s clinical studies planned for the United States and Europe and those planned in Thailand, Viet Nam and Indonesia to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases, and the World Health Organization.

MORE ON THIS TOPIC